A Study of IBI363 in Subjects With Advanced Malignancies
This is an open-label, multicenter Phase Ib study to evaluate the safety, tolerability, and efficacy of IBI363 in advanced malignancies patients
Advanced Malignancies
DRUG: IBI363 + chemotherapy|DRUG: IBI363 + Investigator's Choice SOC
Adverse Enent (AE), Adverse events will be assessed by investigator(s) according to NCI-CTCAE v5.0, Up to 90 days after the last administration|Treatment-Emergent AE (TEAE), Adverse events will be assessed by investigator(s) according to NCI-CTCAE v5.0, Up to 90 days after the last administration|Adverse Event of Special Interest (AESI), Adverse events will be assessed by investigator(s) according to NCI-CTCAE v5.0, Up to 90 days after the last administration|Serious Adverse Event (SAE), Adverse events will be assessed by investigator(s) according to NCI-CTCAE v5.0, Up to 90 days after the last administration|Objective response rate (ORR), ORR is defined as the proportion of participants with a complete response (CR) or partial response (PR)., Through out the study (up to 2 years)|disease control rate (DCR), DCR is defined as the proportion of participants with a complete response (CR) or partial response (PR) or stable disease(SD), Through out the study (up to 2 years)|time to response (TTR), TTR is defined as the time from the date of first dose of study drug to the date of first documented tumor response (CR/PR), Through out the study (up to 2 years)|duration of response (DoR), DoR is defined as the time from the date of first documented tumor response (CR/PR) until PD/death, Through out the study (up to 2 years)|progression-free survival (PFS), PFS is defined as the time from the date of first dose of study drug to the date of the first documented progression or death due to any cause, whichever occurs first, Through out the study (up to 2 years)|Overall survival (OS), OS is defined as the time from the date of first dose of study drug until the date of death from any cause., Through out the study (an average of 2 years)
Plasma concentration (Cmax) of IBI363, PK parameters maximum concentration (Cmax) of IBI363, Up to 2 years|Area under the curve (AUC) of IBI363, PK parameters area under the curve (AUC)?of IBI363, Up to 2 years|Half-life (T1/2) of IBI363, PK parameters half-life (t1/2)?of IBI363, Up to 2 years|Clearance (CL) of IBI363, PK parameters clearance rate of IBI363, Up to 2 years|Volume of distribution (V) of IBI363, PK parameters apparent volume of distribution(V)?of IBI363, Up to 2 years|Immunogenicity of IBI363, Incidence of anti-drug (IBI363) antibody, Up to 2 years
This is an open-label, multicenter Phase Ib study to evaluate the safety, tolerability, and efficacy of IBI363 in advanced malignancies patients